Literature DB >> 34866403

15-Lipoxygenase worsens renal fibrosis, inflammation, and metabolism in a murine model of ureteral obstruction.

John R Montford1,2, Colin Bauer2, Jeremy Rahkola1, Julie A Reisz3, Deanna Floyd1, Katharina Hopp2,4, Danielle E Soranno2,4,5, Jelena Klawitter2, Mary C M Weiser-Evans2,4,6, Raphael Nemenoff2,4,6, Sarah Faubel1,2, Seth B Furgeson2,4,7.   

Abstract

15-Lipoxygenase (15-LO) is a nonheme iron-containing dioxygenase that has both pro- and anti-inflammatory roles in many tissues and disease states. 15-LO is thought to influence macrophage phenotype, and silencing 15-LO reduces fibrosis after acute inflammatory triggers. The goal of the present study was to determine whether altering 15-LO expression influences inflammation and fibrogenesis in a murine model of unilateral ureteral obstruction (UUO). C57BL/6J mice, 15-LO knockout (Alox15-/-) mice, and 15-LO transgenic overexpressing (15LOTG) mice were subjected UUO, and kidneys were analyzed at 3, 10, and 14 days postinjury. Histology for fibrosis, inflammation, cytokine quantification, flow cytometry, and metabolomics were performed on injured tissues and controls. PD146176, a specific 15-LO inhibitor, was used to complement experiments involving knockout animals. Compared with wild-type animals undergoing UUO, Alox15-/- mouse kidneys had less proinflammatory, profibrotic message along with less fibrosis and macrophage infiltration. PD146176 inhibited 15-LO and resulted in reduced fibrosis and macrophage infiltration similar to Alox15-/- mice. Flow cytometry revealed that Alox15-/- UUO-injured kidneys had a dynamic change in macrophage phenotype, with an early blunting of CD11bHiLy6CHi "M1" macrophages and an increase in anti-inflammatory CD11bHiLy6CInt "M2c" macrophages and reduced expression of the fractalkine receptor chemokine (C-X3-C motif) receptor 1. Many of these findings were reversed when UUO was performed on 15LOTG mice. Metabolomics analysis revealed that wild-type kidneys developed a glycolytic shift postinjury, while Alox15-/- kidneys exhibited increased oxidative phosphorylation. In conclusion, 15-LO manipulation by genetic or pharmacological means induces dynamic changes in the inflammatory microenvironment in the UUO model and appears to be critical in the progression of UUO-induced fibrosis.NEW & NOTEWORTHY 15-Lipoxygenase (15-LO) has both pro- and anti-inflammatory functions in leukocytes, and its role in kidney injury and repair is unexplored. Our study showed that 15-LO worsens inflammation and fibrosis in a rodent model of chronic kidney disease using genetic and pharmacological manipulation. Silencing 15-LO promotes an increase in M2c-like wound-healing macrophages in the kidney and alters kidney metabolism globally, protecting against anaerobic glycolysis after injury.

Entities:  

Keywords:  eicosanoids; fibrosis; lipoxygenase; macrophage; metabolism

Mesh:

Substances:

Year:  2021        PMID: 34866403      PMCID: PMC8742724          DOI: 10.1152/ajprenal.00214.2021

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  35 in total

1.  A role for 12/15-lipoxygenase-derived proresolving mediators in postoperative ileus: protectin DX-regulated neutrophil extravasation.

Authors:  Kathy Stein; Melissa Stoffels; Mariola Lysson; Bianca Schneiker; Oliver Dewald; Gerhard Krönke; Jörg C Kalff; Sven Wehner
Journal:  J Leukoc Biol       Date:  2015-08-20       Impact factor: 4.962

Review 2.  Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology.

Authors:  Charles N Serhan
Journal:  Mol Aspects Med       Date:  2017-03-03

3.  A three-minute method for high-throughput quantitative metabolomics and quantitative tracing experiments of central carbon and nitrogen pathways.

Authors:  Travis Nemkov; Kirk C Hansen; Angelo D'Alessandro
Journal:  Rapid Commun Mass Spectrom       Date:  2017-04-30       Impact factor: 2.419

4.  High-Throughput Metabolomics: Isocratic and Gradient Mass Spectrometry-Based Methods.

Authors:  Travis Nemkov; Julie A Reisz; Sarah Gehrke; Kirk C Hansen; Angelo D'Alessandro
Journal:  Methods Mol Biol       Date:  2019

Review 5.  Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis.

Authors:  Jianguo Xia; David S Wishart
Journal:  Curr Protoc Bioinformatics       Date:  2016-09-07

6.  CX3CR1 reduces kidney fibrosis by inhibiting local proliferation of profibrotic macrophages.

Authors:  Daniel R Engel; Torsten A Krause; Sarah L Snelgrove; Stephanie Thiebes; Michael J Hickey; Peter Boor; A Richard Kitching; Christian Kurts
Journal:  J Immunol       Date:  2015-01-16       Impact factor: 5.422

7.  Alternatively activated macrophages in the pathogenesis of chronic kidney allograft injury.

Authors:  Yohei Ikezumi; Toshiaki Suzuki; Takeshi Yamada; Hiroya Hasegawa; Utako Kaneko; Masanori Hara; Toshio Yanagihara; David J Nikolic-Paterson; Akihiko Saitoh
Journal:  Pediatr Nephrol       Date:  2014-12-09       Impact factor: 3.714

8.  Lipoxygenase activity in rat kidney glomeruli, glomerular epithelial cells, and cortical tubules.

Authors:  K Jim; A Hassid; F Sun; M J Dunn
Journal:  J Biol Chem       Date:  1982-09-10       Impact factor: 5.157

Review 9.  The double-edged role of 12/15-lipoxygenase during inflammation and immunity.

Authors:  Jochen A Ackermann; Katharina Hofheinz; Mario M Zaiss; Gerhard Krönke
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2016-07-30       Impact factor: 5.228

10.  Proteomic analysis reveals a protective role of specific macrophage subsets in liver repair.

Authors:  Wenting Yang; Xinyuan Zhao; Yuandong Tao; Yan Wu; Fuchu He; Li Tang
Journal:  Sci Rep       Date:  2019-02-27       Impact factor: 4.379

View more
  1 in total

Review 1.  Molecular Mechanisms of Cellular Injury and Role of Toxic Heavy Metals in Chronic Kidney Disease.

Authors:  Manish Mishra; Larry Nichols; Aditi A Dave; Elizabeth H Pittman; John P Cheek; Anasalea J V Caroland; Purva Lotwala; James Drummond; Christy C Bridges
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.